Diabetes pills may boost brain power in new trial

NCT ID NCT05313529

First seen Jan 04, 2026 · Last updated May 11, 2026 · Updated 27 times

Summary

This study tests three common diabetes medications (liraglutide, empagliflozin, and linagliptin) to see if they can improve memory and thinking in people with type 2 diabetes who have mild cognitive impairment. About 396 adults aged 40-75 will take one of the drugs for 48 weeks, with a 28-week follow-up. The goal is to see if these drugs can help reverse early signs of dementia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Department of Endocrinology, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University

    Changzhou, Jiangsu, 213000, China

  • Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University

    Nanjing, Jiangsu, 210000, China

  • Department of Endocrinology, The Affiliated Wuxi People's Hospital of Nanjing Medical University

    Wuxi, Jiangsu, 214000, China

  • Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, 210008, China

  • Department of Endocrinology, the Affiliated Jiangning Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 211100, China

Conditions

Explore the condition pages connected to this study.